title: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma.
abstract: BACKGROUND
  Although inhaled corticosteroids have an established role in the treatment of asthma, studies have tended to concentrate on non-smokers and little is known about the possible effect of cigarette smoking on the efficacy of treatment with inhaled steroids in asthma. A study was undertaken to investigate the effect of active cigarette smoking on responses to treatment with inhaled corticosteroids in patients with mild asthma.
  
  
  METHODS
  The effect of treatment with inhaled fluticasone propionate (1000 microg daily) or placebo for 3 weeks was studied in a double blind, prospective, randomised, placebo controlled study of 38 steroid naïve adult asthmatic patients (21 non-smokers). Efficacy was assessed using morning and evening peak expiratory flow (PEF) readings, spirometric parameters, bronchial hyperreactivity, and sputum eosinophil counts. Comparison was made between responses to treatment in non-smoking and smoking asthmatic patients.
  
  
  RESULTS
  There was a significantly greater increase in mean morning PEF in non-smokers than in smokers following inhaled fluticasone (27 l/min v -5 l/min). Non-smokers had a statistically significant increase in mean morning PEF (27 l/min), mean forced expiratory volume in 1 second (0.17 l), and geometric mean PC20 (2.6 doubling doses), and a significant decrease in the proportion of sputum eosinophils (-1.75%) after fluticasone compared with placebo. No significant changes were observed in the smoking asthmatic patients for any of these parameters.
  
  
  CONCLUSIONS
  Active cigarette smoking impairs the efficacy of short term inhaled corticosteroid treatment in mild asthma. This finding has important implications for the management of patients with mild asthma who smoke.
authors.affiliation: Departments of Respiratory Medicine and Immunology, Western Infirmary, Glasgow G11 6NT, UK.
authors.forename: G W
authors.initials: GW
authors.lastname: Chalmers
authors.forename: K J
authors.initials: KJ
authors.lastname: Macleod
authors.forename: S A
authors.initials: SA
authors.lastname: Little
authors.forename: L J
authors.initials: LJ
authors.lastname: Thomson
authors.forename: C P
authors.initials: CP
authors.lastname: McSharry
authors.forename: N C
authors.initials: NC
authors.lastname: Thomson
mesh_terms: D000280:Administration, Inhalation; D000287:Administration, Topical; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000503:physiopathology / Q000517:prevention & control; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D012907:Smoking / Q000009:adverse effects* / Q000503:physiopathology; D013183:Sputum / Q000166:cytology
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D000068298:Fluticasone